Most-Downgraded StocksMost-DowngradedNASDAQ:IONS Ionis Pharmaceuticals (IONS) Stock Price, News & Analysis $46.34 +1.50 (+3.35%) As of 10:34 AM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Ionis Pharmaceuticals Stock (NASDAQ:IONS) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Ionis Pharmaceuticals alerts:Sign Up Key Stats Today's Range$45.75▼$47.4250-Day Range$44.84▼$64.2752-Week Range$44.66▼$86.74Volume545,662 shsAverage Volume2.53 million shsMarket Capitalization$7.70 billionP/E RatioN/ADividend YieldN/APrice Target$90.80Consensus RatingModerate Buy Company Overview Ionis Pharmaceuticals, Inc. is a biotechnology company that discovers and develops medicines using antisense technology, which is designed to target RNA and influence the production of disease-related proteins. The company focuses on neurological, cardiovascular, metabolic and other serious diseases for which there remains a significant unmet medical need. Ionis has developed several approved therapies, including SPINRAZA (nusinersen) for spinal muscular atrophy, QALSODY (tofersen) for a form of amyotrophic lateral sclerosis, TEGSEDI (inotersen) for hereditary transthyretin-mediated amyloidosis and WAYLIVRA (volanesorsen) for familial chylomicronemia syndrome in certain markets. Its pipeline also includes eplontersen, an antisense medicine developed with AstraZeneca for transthyretin amyloidosis. Founded in 1989, Ionis is headquartered in Carlsbad, California. The company develops medicines independently and through collaborations with pharmaceutical partners, supporting commercialization and distribution across international markets. Ionis is led by Chief Executive Officer Brett P. Monia.AI Generated. May Contain Errors. Read More Ionis Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks65th Percentile Overall ScoreIONS MarketRank™: Ionis Pharmaceuticals scored higher than 65% of companies evaluated by MarketBeat, and ranked 351st out of 900 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingIonis Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.73, and is based on no strong buy ratings, 17 buy ratings, 4 hold ratings, and 1 sell rating.Upside PotentialIonis Pharmaceuticals has a consensus price target of $90.80, representing about 95.0% upside from its current price of $46.55.Amount of Analyst CoverageIonis Pharmaceuticals has been the subject of 18 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Ionis Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Ionis Pharmaceuticals are expected to grow in the coming year, from ($3.57) to ($2.36) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Ionis Pharmaceuticals is -12.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Ionis Pharmaceuticals is -12.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioIonis Pharmaceuticals has a P/B Ratio of 15.42. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Ionis Pharmaceuticals' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted12.82% of the float of Ionis Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverIonis Pharmaceuticals has a short interest ratio ("days to cover") of 9.18.Change versus previous monthShort interest in Ionis Pharmaceuticals has recently increased by 0.07%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldIonis Pharmaceuticals does not currently pay a dividend.Dividend GrowthIonis Pharmaceuticals does not have a long track record of dividend growth. News and Social Media2.8 / 5News Sentiment0.47 News SentimentIonis Pharmaceuticals has a news sentiment score of 0.47. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.79 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Ionis Pharmaceuticals this week, compared to 9 articles on an average week.Search InterestOnly 20 people have searched for IONS on MarketBeat in the last 30 days. This is a decrease of -23% compared to the previous 30 days.MarketBeat Follows10 people have added Ionis Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership2.2 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Ionis Pharmaceuticals insiders have sold 1,095.48% more of their company's stock than they have bought. Specifically, they have bought $1,058,700.00 in company stock and sold $12,656,566.00 in company stock.Percentage Held by Insiders1.81% of the stock of Ionis Pharmaceuticals is held by insiders.Percentage Held by Institutions93.86% of the stock of Ionis Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Ionis Pharmaceuticals' insider trading history. Receive IONS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ionis Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. IONS Stock News HeadlinesIonis Pharmaceuticals, Inc. (IONS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeptember 16 at 6:42 PM | seekingalpha.comGuggenheim Reaffirms Their Buy Rating on Ionis Pharmaceuticals (IONS)September 16 at 8:41 AM | theglobeandmail.comALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings research points to the first half of 2026 as a particularly rough stretch for certain holdings. Some of America's most popular stocks could take serious damage as a radical market shift plays out. Analysts at Weiss Ratings have identified five names you may want to remove from your portfolio before this unfolds. If any of these are in your portfolio, now is the time to review your positions.September 17 at 1:00 AM | Weiss Ratings (Ad)Analysts Offer Insights on Healthcare Companies: Scholar Rock Holding (SRRK), Axsome Therapeutics (AXSM) and Ionis Pharmaceuticals (IONS)September 15 at 5:39 PM | theglobeandmail.comIonis Has Its First Neurology Launch, But Can Zanvastro Justify Its $285,000 Price?September 11, 2026 | insidermonkey.comEquities Analysts Offer Predictions for IONS Q4 EarningsSeptember 11, 2026 | americanbankingnews.comIonis Pharmaceuticals, Inc. (IONS) Presents at Wells Fargo 21st Annual Healthcare Conference TranscriptSeptember 10, 2026 | seekingalpha.comCanaccord Genuity Group Issues Pessimistic Forecast for Ionis Pharmaceuticals (NASDAQ:IONS) Stock PriceSeptember 10, 2026 | americanbankingnews.comSee More Headlines IONS Stock Analysis - Frequently Asked Questions How have IONS shares performed this year? Ionis Pharmaceuticals' stock was trading at $79.11 at the beginning of 2026. Since then, IONS shares have decreased by 41.2% and is now trading at $46.5540. How were Ionis Pharmaceuticals' earnings last quarter? Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) posted its quarterly earnings data on Wednesday, April, 29th. The company reported ($0.56) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.85) by $0.29. The firm's quarterly revenue was up 86.4% on a year-over-year basis. Read the conference call transcript. Who are Ionis Pharmaceuticals' major shareholders? Ionis Pharmaceuticals' top institutional investors include Alyeska Investment Group L.P. (0.85%), Bank of America Corp DE (0.48%), Connor Clark & Lunn Investment Management Ltd. (0.41%) and TimesSquare Capital Management LLC (0.37%). Insiders that own company stock include Brett P Monia, Spencer R Berthelsen, Elizabeth L Hougen, Eugene Schneider, C Frank Bennett, Brian Birchler, Patrick R O'neil, Richard S Geary, B Lynne Parshall, Joseph H Wender, Onaiza Cadoret-Manier, Michael R Hayden, Kyle Jenne, Holly B Kordasiewicz, Eric Swayze, Joseph Baroldi, Shannon L Devers, Joseph Klein III and Allene M Diaz. View institutional ownership trends. How do I buy shares of Ionis Pharmaceuticals? Shares of IONS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Ionis Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Ionis Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Arista Networks (ANET), Adobe (ADBE) and CrowdStrike (CRWD). Company Calendar Last Earnings4/29/2026Today9/17/2026Next Earnings (Estimated)11/04/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (2m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 IONS's financial health is in the Red zone, according to TradeSmith. IONS has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:IONS CIK874015 Webwww.ionis.com Phone(760) 931-9200Fax760-603-2700Employees1,402Year Founded1989Price Target and Rating Average Price Target for Ionis Pharmaceuticals$90.80 High Price Target$129.00 Low Price Target$54.00 Potential Upside/Downside+96.7%Consensus RatingModerate Buy Rating Score (0-4)2.73 Research Coverage22 Analysts Profitability EPS (Trailing Twelve Months)($3.46) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$381.39 million Net Margins-64.76% Pretax Margin-64.30% Return on Equity-111.08% Return on Assets-17.41% Debt Debt-to-Equity Ratio3.07 Current Ratio7.89 Quick Ratio7.73 Sales & Book Value Annual Sales$944 million Price / Sales8.13 Cash FlowN/A Price / Cash FlowN/A Book Value$3.02 per share Price / Book15.29Miscellaneous Outstanding Shares166,180,000Free Float163,176,000Market Cap$7.67 billion OptionableOptionable Beta0.42 Social Links The Infrastructure's Backbone: 10 Stocks Powering the AI BuildoutThe AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.Get This Free Report This page (NASDAQ:IONS) was last updated on 9/17/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredThese gold assets are priced for $1,800 gold [it's over $4,000]Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...Golden Portfolio | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredYour withdrawal order could cost you in taxesIf you have $2M or more saved, the 4% rule points to roughly $92,000 a year - but it's a single-variable answe...SmartAsset | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ionis Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ionis Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
